Common Stock, par value $0.001 per share
- Symbol
- ARTL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Artelo Biosciences, Inc.
ARTLNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On July 22, 2026, the Securities and Exchange Commission (the “SEC”) approved The Nasdaq Stock Market LLC’s (“Nasdaq”) new listing compliance rule that requires listed companies to maintain a market value of listed securities (“MVLS”) of at least $5,000,000 (the “$5M MVLS Rule”).…
Company context
We are currently developing a novel, benzimidazole dual cannabinoid (CB) agonist that targets both the CB1 and CB2 peripheral receptors. This synthetic small molecule program is a G protein-coupled receptor (“GPCR”) designated ART27.13 and was initially developed by AstraZeneca plc. We are developing ART27.13 as a potential treatment for cancer-related anorexia and it is currently in a Phase 1b/2a trial, titled the Cancer Appetite Recovery Study (“CAReS”). In an interim analysis of the on-going Phase 2a CAReS trial, patients with cancer anorexia receiving ART27.13 demonstrated a mean weight gain of over 6% compared to a 5% loss in the placebo group, while maintaining a safety profile similar to the Phase 1b despite doses up to twice the previous maximum. Currently there is no FDA approved treatment for cancer anorexia cachexia syndrome.
Current securities
Registered securities in this filing
ARTELO BIOSCIENCES, INC. · 8-K · Filed 2026-10-09
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On July 22, 2026, the Securities and Exchange Commission (the “SEC”) approved The Nasdaq Stock Market LLC’s (“Nasdaq”) new listing compliance rule that requires listed companies to maintain a market value of listed securities (“MVLS”) of at least $5,000,000 (the “$5M MVLS Rule”). Companies that fall below this threshold may be subject to delisting proceedings unless they can demonstrate a plan to regain compliance within a specified period.
Approximately 180 companies listed on Nasdaq were initially identified as having an MVLS below the new threshold, including Artelo Biosciences, Inc. (the “Company”). On July 29, 2026, a temporary stay of the $5M MVLS Rule was announced. On October 5, 2026, the SEC published a notice from Nasdaq for a proposed rule change to modify the operative date of the $5M MVLS Rule to be upon termination of the temporary stay. Comments on the proposed rule change are due by October 29, 2026. As of the date of this filing, the Company has no information regarding how long the stay will remain in effect, whether the $5M MVLS Rule will be reinstated in its current form, or whether any modifications to the rule will be adopted.
The Company intends to monitor developments relating to the $5M MVLS Rule and, if the rule takes effect in a form that applies to the Company, expects to consider the steps available to it to regain or maintain compliance. Depending on the final form of the rule and the circumstances at the time, those steps could include, among other things, raising capital through the Company’s existing at-the-market equity offering program or other equity or equity-linked financings, actions with respect to outstanding warrants or other securities, continued advancement of the Company’s development programs, management of operating expenses, and other corporate actions. The Company has not committed to any particular course of action, is not soliciting proposals for any transaction, and does not intend to disclose further developments unless and until it determines that disclosure is appropriate or required. There can be no assurance that the Company will take any particular action, that any particular transaction or strategy will be completed or that any such action will result in the Company achieving or maintaining compliance with the $5M MVLS Rule.